Levetiracetam Tablet
Product Images NDC 43063-499

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 43063-499). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063499 Label (43063499)

This is a description of a medication containing LevETIRAcetam USP 500mg in tablet form. There are three bottles with 60 tablets each, and they have the same ReOrder and LOT numbers. The expiration date is 09/2021. The tablets are yellow, oval/brelined, with the marking 1015 500mg. The package insert provides only Dosage and Storage information, and there is a warning to keep away from children. The instructions indicate to take the tablet(s) 'times a day'. The text includes a phone number to call the doctor for medical advice about side effects, and to report side effects to the FDA. The last line is not readable.*

FDA Label Image

Ectdmodule1usa1

FDA Label Image

Ectdmodule1usa2

FDA Label Image

Ectdmodule1usa3

This is a chart depicting the percentage of patients in a study who were given a placebo or varying doses of levetiracetam, a medication commonly used to treat epilepsy. The percentages represent the proportion of patients in each group, with 35.2% receiving a placebo, 20.8% receiving 1000mg/day of levetiracetam, and 6.3% receiving 2000mg/day of levetiracetam. The study included 111 patients in the placebo group, and 106 and 105 patients in the two levetiracetam dosage groups, respectively.*

FDA Label Image

Ectdmodule1usa4

FDA Label Image

Ectdmodule1usa5

This appears to be a table showing percentages of patients in a study related to the medication Levetiracetam compared to a placebo group. It is unclear what the percentages represent as there are no column or row labels. The text also includes special characters such as "%" and "@", which may suggest that the original document was not properly converted to text via .*

FDA Label Image

Ectdmodule1usa6

FDA Label Image

Ectdmodule1usa7

The text "45.2%" appears to be a statistic and does not provide enough information to generate a useful description. The rest of the text refers to a study with a placebo group and a group taking levetiracetam, a medication commonly used to treat seizures. However, without more context or information about the study, a description cannot be provided.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.